$FNCH
Finch Therapeutics Group, Inc.

2021 Q4 Form 10-Q Financial Statement

#000095017021004159 Filed on November 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $806.0K $11.34M $1.771M
YoY Change -55.4% 540.49%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.065M $5.739M $2.807M
YoY Change -20.51% 104.45%
% of Gross Profit
Research & Development $14.80M $15.54M $9.045M
YoY Change 72.73% 71.77%
% of Gross Profit
Depreciation & Amortization $678.0K $638.0K $205.0K
YoY Change 213.89% 211.22%
% of Gross Profit
Operating Expenses $19.87M $21.28M $11.85M
YoY Change 32.99% 79.51%
Operating Profit -$9.933M -$10.08M
YoY Change -1.47%
Interest Expense $8.000K $8.000K -$7.000K
YoY Change 700.0% -214.29%
% of Operating Profit
Other Income/Expense, Net -$29.00K -$22.00K -$9.000K
YoY Change -154.72% 144.44%
Pretax Income -$19.06M -$9.955M -$10.09M
YoY Change 45.56% -1.34%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$19.06M -$9.955M -$10.09M
YoY Change 45.56% -1.34%
Net Earnings / Revenue -2364.14% -87.76% -569.73%
Basic Earnings Per Share -$0.21
Diluted Earnings Per Share -$400.5K -$209.8K -$214.0K
COMMON SHARES
Basic Shares Outstanding 47.48M 47.45M
Diluted Shares Outstanding 47.45M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $133.5M $149.2M
YoY Change
Cash & Equivalents $133.5M $149.2M $112.4M
Short-Term Investments
Other Short-Term Assets $8.576M $4.568M
YoY Change
Inventory
Prepaid Expenses
Receivables $494.0K $2.399M
Other Receivables $0.00 $0.00
Total Short-Term Assets $142.6M $156.2M
YoY Change 34.27%
LONG-TERM ASSETS
Property, Plant & Equipment $19.64M $19.55M
YoY Change 180.34%
Goodwill $18.06M $18.06M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.905M $4.041M
YoY Change 2352.5%
Total Long-Term Assets $82.82M $76.81M
YoY Change 39.96%
TOTAL ASSETS
Total Short-Term Assets $142.6M $156.2M
Total Long-Term Assets $82.82M $76.81M
Total Assets $225.4M $233.0M
YoY Change 36.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.737M $1.382M
YoY Change 42.58%
Accrued Expenses $11.05M $7.469M
YoY Change
Deferred Revenue $0.00 $0.00
YoY Change -100.0%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.79M $8.851M
YoY Change 28.77%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $7.000K $174.0K
YoY Change -96.83%
Total Long-Term Liabilities $7.000K $174.0K
YoY Change -99.66%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.79M $8.851M
Total Long-Term Liabilities $7.000K $174.0K
Total Liabilities $23.15M $13.18M
YoY Change -17.35%
SHAREHOLDERS EQUITY
Retained Earnings -$161.0M -$141.9M
YoY Change 56.56%
Common Stock $363.2M $361.7M
YoY Change 5003.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $202.2M $219.8M -$85.53M
YoY Change
Total Liabilities & Shareholders Equity $225.4M $233.0M
YoY Change 36.31%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$19.06M -$9.955M -$10.09M
YoY Change 45.56% -1.34%
Depreciation, Depletion And Amortization $678.0K $638.0K $205.0K
YoY Change 213.89% 211.22%
Cash From Operating Activities -$13.79M -$14.35M -$6.914M
YoY Change 34.09% 107.55%
INVESTING ACTIVITIES
Capital Expenditures -$2.002M -$2.364M -$217.0K
YoY Change -6.71% 989.4%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$2.002M -$2.364M -$217.0K
YoY Change -6.71% 989.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 70.00K 45.00K 89.90M
YoY Change -130.57% -99.95%
NET CHANGE
Cash From Operating Activities -13.79M -14.35M -6.914M
Cash From Investing Activities -2.002M -2.364M -217.0K
Cash From Financing Activities 70.00K 45.00K 89.90M
Net Change In Cash -15.72M -16.67M 82.77M
YoY Change 24.19% -120.14%
FREE CASH FLOW
Cash From Operating Activities -$13.79M -$14.35M -$6.914M
Capital Expenditures -$2.002M -$2.364M -$217.0K
Free Cash Flow -$11.78M -$11.99M -$6.697M
YoY Change 44.85% 78.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001733257
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40227
dei Entity Registrant Name
EntityRegistrantName
FINCH THERAPEUTICS GROUP, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-3433558
dei Entity Address Address Line1
EntityAddressAddressLine1
200 Inner Belt Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
dei Entity Address City Or Town
EntityAddressCityOrTown
Somerville
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02143
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
229-6499
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
FNCH
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
47478726
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
149200000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
99710000
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2399000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1034000
CY2021Q3 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
0
CY2020Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
61000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4568000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5359000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
156167000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
106164000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19546000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7004000
CY2021Q3 fnch In Process Research And Development
InProcessResearchAndDevelopment
32900000
CY2020Q4 fnch In Process Research And Development
InProcessResearchAndDevelopment
32900000
CY2021Q3 us-gaap Goodwill
Goodwill
18057000
CY2020Q4 us-gaap Goodwill
Goodwill
18057000
CY2021Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
0
CY2020Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
1013000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2268000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
0
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4041000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
200000
CY2021Q3 us-gaap Assets
Assets
232979000
CY2020Q4 us-gaap Assets
Assets
165338000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1382000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2621000
CY2021Q3 fnch Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
7469000
CY2020Q4 fnch Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
5228000
CY2021Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
0
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
266000
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3371000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8851000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11486000
CY2021Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
3461000
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
3461000
CY2021Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
0
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
10260000
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1808000
CY2021Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
692000
CY2020Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
766000
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
174000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
221000
CY2021Q3 us-gaap Liabilities
Liabilities
13178000
CY2020Q4 us-gaap Liabilities
Liabilities
28002000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
598232153
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47454962
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47454962
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8391793
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8391793
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
47000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
361694000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
7109000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-141940000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-102835000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
219801000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-95718000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
232979000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
165338000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11343000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1771000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17726000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5912000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15537000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9045000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42476000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24577000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5739000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2807000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16173000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7639000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
21276000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
11852000
us-gaap Operating Expenses
OperatingExpenses
58649000
us-gaap Operating Expenses
OperatingExpenses
32216000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9933000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10081000
us-gaap Operating Income Loss
OperatingIncomeLoss
-40923000
us-gaap Operating Income Loss
OperatingIncomeLoss
-26304000
fnch Gains Losses On Extinguishment Of Debt Includes Accrued Interest
GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest
1827000
CY2021Q3 us-gaap Investment Income Net
InvestmentIncomeNet
8000
CY2020Q3 us-gaap Investment Income Net
InvestmentIncomeNet
-7000
us-gaap Investment Income Net
InvestmentIncomeNet
14000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-30000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-23000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-51000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-22000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1818000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-54000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9955000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10090000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39105000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26250000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9955000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-10090000
us-gaap Net Income Loss
NetIncomeLoss
-39105000
us-gaap Net Income Loss
NetIncomeLoss
-26250000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-9955000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-10090000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-39105000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-26250000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.22
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.07
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.25
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47445195
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8258537
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36408506
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8065730
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-59535000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15000
CY2020Q1 fnch Stock Issued During Period Value Vesting Of Restricted Stock
StockIssuedDuringPeriodValueVestingOfRestrictedStock
3000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
75000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-7901000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-67343000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2020Q2 fnch Stock Issued During Period Value Vesting Of Restricted Stock
StockIssuedDuringPeriodValueVestingOfRestrictedStock
3000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
85000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-8259000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-75510000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000
CY2020Q3 fnch Stock Issued During Period Value Vesting Of Restricted Stock
StockIssuedDuringPeriodValueVestingOfRestrictedStock
2000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
56000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-10090000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-85532000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-95718000
CY2021Q1 fnch Conversion Of Redeemable Convertible Preferred Stock Into Common Stock Upon Initial Public Offering
ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering
233053000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
115714000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
54000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
335000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-13981000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
239457000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000
CY2021Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
10000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
574000
us-gaap Share Based Compensation
ShareBasedCompensation
2755000
us-gaap Share Based Compensation
ShareBasedCompensation
223000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
905000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-15169000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
228193000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
48000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1515000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9955000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
219801000
us-gaap Profit Loss
ProfitLoss
-39105000
us-gaap Profit Loss
ProfitLoss
-26250000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1623000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1808000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
28000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-13000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1365000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-388000
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-61000
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-3278000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-791000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1802000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
3824000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1297000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
448000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2784000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-112000
fnch Increase Decrease In Due To Related Parties Current Excluding Accounts Payable
IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable
-266000
fnch Increase Decrease In Due To Related Parties Current Excluding Accounts Payable
IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable
292000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-13630000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1340000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-37000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
337000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-53346000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21047000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13981000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
487000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
62000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13919000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-487000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
118575000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
fnch Proceeds From Issuance Of Series D Convertible Preferred Stock
ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock
0
fnch Proceeds From Issuance Of Series D Convertible Preferred Stock
ProceedsFromIssuanceOfSeriesDConvertiblePreferredStock
90000000
fnch Payment Of Redeemable Convertible Preferred Stock Issuance Costs
PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts
0
fnch Payment Of Redeemable Convertible Preferred Stock Issuance Costs
PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts
96000
fnch Proceeds From Underwriters Exercise Of Overallotment Option Net Of Underwriting Discounts And Commissions And Initial Public Offering Costs
ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts
3049000
fnch Proceeds From Underwriters Exercise Of Overallotment Option Net Of Underwriting Discounts And Commissions And Initial Public Offering Costs
ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts
0
fnch Principal Payments On Capital Lease Obligation
PrincipalPaymentsOnCapitalLeaseObligation
25000
fnch Principal Payments On Capital Lease Obligation
PrincipalPaymentsOnCapitalLeaseObligation
38000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
30000
fnch Proceeds From Paycheck Protection Program Loan
ProceedsFromPaycheckProtectionProgramLoan
0
fnch Proceeds From Paycheck Protection Program Loan
ProceedsFromPaycheckProtectionProgramLoan
1808000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2659000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
119040000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
91704000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
51775000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
42396000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
151684000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
112566000
us-gaap Interest Paid Net
InterestPaidNet
7000
us-gaap Interest Paid Net
InterestPaidNet
8000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
70170000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
99909000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
218000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
209000
us-gaap Stock Issued1
StockIssued1
233053000
us-gaap Stock Issued1
StockIssued1
0
fnch Forgiveness Of Paycheck Protection Program
ForgivenessOfPaycheckProtectionProgram
1808000
fnch Forgiveness Of Paycheck Protection Program
ForgivenessOfPaycheckProtectionProgram
0
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
149200000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112366000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
2484000
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
200000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
151684000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
112566000
CY2021Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
2900000
CY2021Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2020Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
1000000.0
CY2021Q3 fnch Transfers Between Fair Value Levels
TransfersBetweenFairValueLevels
0
CY2020Q4 fnch Transfers Between Fair Value Levels
TransfersBetweenFairValueLevels
0
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
23094000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9033000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3548000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2029000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19546000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7004000
us-gaap Depreciation
Depreciation
1600000
us-gaap Depreciation
Depreciation
600000
CY2021Q3 fnch Accrued Research And Development
AccruedResearchAndDevelopment
2295000
CY2020Q4 fnch Accrued Research And Development
AccruedResearchAndDevelopment
81000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
648000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
711000
CY2021Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2886000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3532000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1640000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
904000
CY2021Q3 fnch Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
7469000
CY2020Q4 fnch Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
5228000
us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
1000000.0
us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
900000
us-gaap Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
100000
us-gaap Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
300000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
467000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6088000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6103000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6255000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
6427000
CY2021Q3 fnch Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
33791000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
59131000
CY2021Q3 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2021Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holder to one vote
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
CY2021Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3191715
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
32326829
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
500000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
0
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1515000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
56000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2755000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
223000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
600000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
300000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9955000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-10090000
us-gaap Net Income Loss
NetIncomeLoss
-39105000
us-gaap Net Income Loss
NetIncomeLoss
-26250000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9955000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10090000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-39105000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26250000
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47445195
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8258537
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36408506
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8065730
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.22
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.07
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.25
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3191715
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25458409

Files In Submission

Name View Source Status
0000950170-21-004159-index-headers.html Edgar Link pending
0000950170-21-004159-index.html Edgar Link pending
0000950170-21-004159.txt Edgar Link pending
0000950170-21-004159-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
fnch-20210930.htm Edgar Link pending
fnch-20210930.xsd Edgar Link pending
fnch-20210930_cal.xml Edgar Link unprocessable
fnch-20210930_def.xml Edgar Link unprocessable
fnch-20210930_htm.xml Edgar Link completed
fnch-20210930_lab.xml Edgar Link unprocessable
fnch-20210930_pre.xml Edgar Link unprocessable
fnch-ex10_1.htm Edgar Link pending
fnch-ex10_2.htm Edgar Link pending
fnch-ex31_1.htm Edgar Link pending
fnch-ex31_2.htm Edgar Link pending
fnch-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending